COMP <GO>
ACTU vs AKTX // FREE CASH FLOW YIELD
Actuate Therapeutics Inc. (NASDAQ) VS. Akari Therapeutics plc ADS (NASDAQ) • 15-METRIC TALLY: ACTU 1
— AKTX 2
■ METRIC PARITY
LAST: $0.34 (+2.06%) • MKT CAP: $18.4M
fcf-yield
—
LAST: $7.84 (-4.85%) • MKT CAP: $18.8M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACTU VS. AKTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACTU | AKTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ACTU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.3 | 47.3 | -14.00 | AKTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.4M | $18.8M | -$399.4K | AKTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACTU REV | AKTX REV | ACTU GROSS % | AKTX GROSS % | ACTU FCF | AKTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $63.0M | $48.4M | — | — | -$19.2M | -$10.6M |
| FY 2024 | $70.5M | $60.6M | — | — | -$21.8M | -$12.6M |
| FY 2023 | $69.9M | $367.9K | — | — | -$21.6M | -$16.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACTU // BETA —
AKTX // BETA —